Choosing Therapies in Ulcerative Colitis

被引:6
作者
Das, Ronit [1 ]
Steinhart, A. Hillary [1 ,2 ]
机构
[1] Mt Sinai Hosp, Gastroenterol IBD, IBD Ctr, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
关键词
INFLAMMATORY-BOWEL-DISEASE; MYCOPHENOLATE-MOFETIL THERAPY; MAINTENANCE THERAPY; DOUBLE-BLIND; EXTRAINTESTINAL MANIFESTATIONS; SUBCUTANEOUS VEDOLIZUMAB; CLINICAL-OUTCOMES; HERPES-ZOSTER; INDUCTION; INFLIXIMAB;
D O I
10.1093/jcag/gwad025
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Those managing ulcerative colitis (UC) must be aware of new treatments. Mesalamine (5-ASA) is the first treatment for mild UC. Steroids have been the first therapy for patients with more severe UC but these are not effective or safe long term. This means that other medicines are needed. Newer advanced therapies are now frequently used. There are several types of advanced therapies. These are the anti-TNF, anti-integrin and anti-IL12/23 agents as well as the JAK inhibitors and sphingosine1-phosphate receptor modulators. All of these are effective in treating UC. Choosing among treatments is complicated. There are multiple factors to think about when choosing a treatment for UC. Without research studies that directly compare the different treatments, the use of any one treatment should be based on effectiveness and safety. Other considerations include specific disease features, patient factors and the preference of patients.
引用
收藏
页码:9 / 21
页数:13
相关论文
共 127 条
[1]   Risk of Melanoma and Non-Melanoma Skin Cancer in Ulcerative Colitis Patients Treated With Thiopurines: A Nationwide Retrospective Cohort [J].
Abbas, Ali M. ;
Almukhtar, Rawaa M. ;
Loftus, Edward V., Jr. ;
Lichtenstein, Gary R. ;
Khan, Nabeel .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (11) :1781-1793
[2]   A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms [J].
Actis, Giovanni Clemente ;
Pellicano, Rinaldo ;
Ribaldone, Davide Giuseppe .
REVIEWS ON RECENT CLINICAL TRIALS, 2019, 14 (01) :4-9
[3]   Novel and Emerging Therapies for Inflammatory Bowel Disease [J].
Al-Bawardy, Badr ;
Shivashankar, Raina ;
Proctor, Deborah D. .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[4]   Mechanisms of action of mycophenolate mofetil [J].
Allison, AC .
LUPUS, 2005, 14 :S2-S8
[5]   Breaking the therapeutic ceiling in drug development in ulcerative colitis [J].
Alsoud, Dahham ;
Verstockt, Bram ;
Fiocchi, Claudio ;
Vermeire, Severine .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07) :S89-S95
[6]   Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease [J].
Ananthakrishnan, Ashwin N. ;
Shi, Hai Yun ;
Tang, Whitney ;
Law, Cindy C. Y. ;
Sung, Joseph J. Y. ;
Chan, Francis K. L. ;
Ng, Siew C. .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (10) :1224-1236
[7]  
[Anonymous], 2022, Gastroenterol Hepatol (N Y), V18, P3
[8]   Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines [J].
Bar-Yoseph, Haggai ;
Waterman, Matti ;
Almog, Ronit ;
Billiet, Thomas ;
Vermeire, Severine ;
Ungar, Bella ;
Yanai, Henit ;
Dotan, Iris ;
Ben-Horin, Shomron ;
Chowers, Yehuda .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (01) :69-75
[9]   Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis [J].
Barberio, Brigida ;
Black, Christopher J. ;
Savarino, Edoardo, V ;
Ford, Alexander C. .
JOURNAL OF CROHNS & COLITIS, 2021, 15 (05) :733-741
[10]  
Ben-Horin Shomron, 2015, Expert Rev Gastroenterol Hepatol, V9 Suppl 1, P27, DOI [10.1586/17474124.2015.1091307, 10.1586/17474124.2015.1091307]